Avallano Appoints New Chief Strategy Officer to Propel AI-Powered Clinical Research

Avallano Appoints New Chief Strategy Officer to Propel AI-Powered Clinical Research

Greenville, S.C. – In a strategic move aimed at revolutionising clinical research, Avallano, a company specialising in AI-enabled clinical trials, has appointed Dr. Michael A. Ibara as its new Chief Strategy Officer (CSO). This announcement, made on June 26, 2024, marks a significant step in the company’s mission to enhance clinical trials through advanced technological solutions.

Dr. Ibara is set to spearhead Avallano’s global strategic initiatives, focusing on the integration and implementation of generative AI technologies designed to address the myriad challenges that patients, clinical trial sites, and sponsors face. Among these innovative solutions are personalised patient chat services and AI-driven medical information processing systems. The company is acutely aware of the importance of maintaining a balance between regulatory compliance and the utilisation of explainable AI, a principle Dr. Ibara will champion.

“Michael’s extensive experience in the biopharmaceutical industry and his innovative approach to data and clinical operations make him the perfect fit for Avallano,” remarked Paul Della Maggiora, Co-Founder and CEO of Avallano. “We have already benefited from Michael’s strategic vision as an advisor and are confident that his leadership will help us achieve our ambitious goals and continue to provide exceptional service to our clients.”

Prior to his new role at Avallano, Dr. Ibara served as Chief Data Officer at Elligo Health Solutions. His tenure at Elligo included the development of pioneering methods to utilise electronic health record (EHR) data for the feasibility and operational planning of clinical trials. One significant achievement was the creation of the first automated system for collecting adverse events directly from EHRs — a leap forward in enhancing both the efficiency and accuracy of clinical trial data collection.

Dr. Ibara’s professional journey is deeply rooted in the biopharmaceutical sector, with senior leadership roles in several major biopharmaceutical and contract research organisations (CROs). He holds a Doctor of Pharmacy (Pharm.D.) degree from the University of Michigan and has completed a Fellowship at the University of North Carolina and Burroughs Wellcome Co.

Expressing his enthusiasm about the new role, Dr. Ibara said, “I am delighted to join Avallano at such an exciting time in the company’s growth. I look forward to working with the team to develop AI-driven solutions to improve clinical research and deliver innovative solutions to help patients get better value from participating in clinical trials.”

Avallano’s investment in AI technologies is geared towards transforming how clinical trials are conducted, aiming to make the process more streamlined and patient-centric. The adoption of AI promises to address prevalent issues such as patient recruitment, data accuracy, and regulatory compliance, all of which are critical in the successful execution of clinical trials.

The arrival of Dr. Ibara comes at a pivotal moment for Avallano, as the company seeks to leverage technology to not only improve the efficiency and effectiveness of clinical trials but also to enhance the overall experience for trial participants. This is particularly significant in an era where the demand for faster and more adaptive clinical research methodologies has never been greater.

As Avallano continues to innovate within the clinical research space, the expertise and leadership of Dr. Ibara are expected to play a crucial role in realising the company’s vision of a more technologically advanced and patient-focused approach to clinical trials.

This development reflects a broader industry trend of integrating AI and other advanced technologies to address longstanding challenges within clinical research, with the ultimate goal of accelerating the delivery of new therapies to patients.